ConductScience.org, home

Gene · 1902

LPAR1: lysophosphatidic acid receptor 1

12 sourcesgene-search-2026-11-11-0.2.0

Download JSON
Cite this record

ConductScience Library. LPAR1: lysophosphatidic acid receptor 1. Genes, record 1902. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/1902

On this page

Gene

Symbol
LPAR1
HGNC
Name
lysophosphatidic acid receptor 1
HGNC
NCBI Gene ID
1902
NCBI Gene
HGNC ID
HGNC:3166
HGNC
Ensembl
ENSG00000198121
NCBI Gene
Aliases
EDG2, Gpcr26, LPA1, Mrec1.3, VZG1, edg-2, rec.1.3, vzg-1
NCBI Gene
Type
protein-coding
NCBI Gene

Proteins1

Reviewed human proteins whose Swiss-Prot entry states the gene.

UniProt entryProteinLengthStructuresGene stated in
Q92633Lysophosphatidic acid receptor 136416Ensembl, GeneID, HGNC

Source UniProt

Patents158

Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.

PublicationPublishedSEQ ID NOProteinSource
US 12599645 B22026-04-1462Q92633Espacenet
JP 2026004568 A2026-01-1452126Q92633Espacenet
JP 2026004568 A2026-01-1452127Q92633Espacenet
JP 2026004568 A2026-01-1452128Q92633Espacenet
EP 4650780 A22025-11-197606Q92633Espacenet
EP 4641201 A22025-10-297626Q92633Espacenet
JP 2025529142 A2025-09-042404Q92633Espacenet
EP 4606896 A12025-08-27111Q92633Espacenet
US 12371689 B22025-07-292404Q92633Espacenet
JP 2025517969 A2025-06-127626Q92633Espacenet

1 to 10 of 158

See all 158 patents

Drugs1

Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.

DrugChEMBL IDMechanismAction
BMS-986020CHEMBL4297270Lysophosphatidic acid receptor Edg-2 antagonistANTAGONIST

Source ChEMBL

Trials2

Trials of those drugs. A trial joins the gene only through a drug that acts on it.

TrialDrugPhaseResults first postedSource
NCT02588625BMS-986020PHASE2ClinicalTrials.gov
NCT01766817BMS-986020PHASE22019-05-22ClinicalTrials.gov

NIH grants1,431

NIH grants whose papers are about the gene, through NIH's grant-paper links.

GrantTitleLPAR1 papersNewest fiscal year
P30CA016672Cancer Center Support Grant192025
P30CA016059Massey Cancer Center - Cancer Center Support Grant92025
T32CA154274Training Grant in Cancer Biology52025
P30ES001247Environmental Agents as Modulators of Disease Processes42025
P01DA009158Endocannabinoid Active Sites as Therapeutic Targets32025
P20GM121307Center for Redox Biology and Cardiovascular Disease32025
P30CA016058Cancer Center Support Grant32025
P30CA086862Cancer Center Support Grant32025
P30CA134274UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTERSUPPORT GRANT32025
P30CA138292Winship Cancer Institute Cancer Center Support Grant32025

1 to 10 of 1,431Source NIH's project files

See all 1,431 nih grants

Papers2,112

Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.

TitleJournalYearPMIDFound bySource
Lactic acid exposure alters lysophosphatidic acid receptor-mediated regulation of growth and motility in pancreatic cancer cells.Mol Cell Biochem202642663874PubTator, text miningPubMed
Context-dependent lysophosphatidic acid signalling in inflammation: evidence hierarchy, myeloid regulation and translational gaps.Inflamm Res202642550283PubTator, text miningPubMed
LPA/LPAR signaling drives temporomandibular disorders-like pain through regulating the expression and sensitization of PIEZO2.Sci Adv202642490435PubTator, text miningPubMed
Lysophosphatidic acid promotes lipid metabolism through AMPK signaling to support Coxsackievirus infection.J Virol202642461030PubTator, text miningPubMed
Biomarker profiles in idiopathic and progressive pulmonary fibrosis after LPA1 antagonism: exploratory analysis from a phase 2 trial of admilparant.Respir Res202642458495PubTator, text miningPubMed
Lysophosphatidic acid (LPA) receptor-mediated signaling in the tumor microenvironment: roles in cancer progression and therapeutic potential.Adv Biol Regul202642456206PubTator, text miningPubMed
M2 Macrophage-Derived ENPP2/LPA Signalling Attenuates UVB-Induced Fibroblast Photoaging via LPAR1/3.Exp Dermatol202642394134PubTator, text miningPubMed
Discovery of PIPE-791, A Potent and Brain-Penetrant Lysophosphatidic Acid Receptor 1 Antagonist with Slow Tight Binding Characteristics for the Treatment of Neuroinflammatory Disorders.J Med Chem202642370792PubTator, text miningPubMed
Targeting phospholipase A2 with arachidonyl trifluoromethyl ketone modulates macrophage activation during Japanese encephalitis virus infection.Med Microbiol Immunol202642189285PubTator, text miningPubMed
A patent review of LPAR1 antagonists (2010 - present).Expert Opin Ther Pat202642132000PubTator, text miningPubMed

1 to 10 of 2,112

See all 2,112 papers

Sources 12

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
  • GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
  • HGNCCC0
  • NCBI GenePublic domain (US government)
  • NIH's project files and grant-paper linksPublic domain
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
  • GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
  • HGNCCC0: https://www.genenames.org/about/license/
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this gene from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/genes/v1/1902

GET https://conductscience.org/api/genes/v1/1902/patents?page=2